(5R,7R,8R,9S,10R)-8,9,10-Tris(acetoxy)-7-(acetoxymethyl)-3-(naphthalen-2-yl)-1,6-dioxa-2-azaspiro[4.5]dec-2-ene

ID: ALA3765349

Chembl Id: CHEMBL3765349

PubChem CID: 127026839

Max Phase: Preclinical

Molecular Formula: C26H27NO10

Molecular Weight: 513.50

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)OC[C@H]1O[C@@]2(CC(c3ccc4ccccc4c3)=NO2)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

Standard InChI:  InChI=1S/C26H27NO10/c1-14(28)32-13-22-23(33-15(2)29)24(34-16(3)30)25(35-17(4)31)26(36-22)12-21(27-37-26)20-10-9-18-7-5-6-8-19(18)11-20/h5-11,22-25H,12-13H2,1-4H3/t22-,23-,24+,25-,26-/m1/s1

Standard InChI Key:  HATURVJNRRIAJG-WSGIOKLISA-N

Alternative Forms

  1. Parent:

    ALA3765349

    ---

Associated Targets(Human)

PYGL Tchem Liver glycogen phosphorylase (1040 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Pygl Liver glycogen phosphorylase (81 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 513.50Molecular Weight (Monoisotopic): 513.1635AlogP: 2.42#Rotatable Bonds: 6
Polar Surface Area: 136.02Molecular Species: NEUTRALHBA: 11HBD: 0
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 0#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 2.45CX LogP: 2.43CX LogD: 2.43
Aromatic Rings: 2Heavy Atoms: 37QED Weighted: 0.42Np Likeness Score: 1.02

References

1. Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S..  (2016)  Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.,  108  [PMID:26708111] [10.1016/j.ejmech.2015.12.004]

Source